Provided by Tiger Trade Technology Pte. Ltd.

Myriad Genetics

3.11
-0.1100-3.42%
Volume:1.75M
Turnover:5.25M
Market Cap:297.32M
PE:-2.58
High:3.12
Open:2.95
Low:2.92
Close:3.22
52wk High:8.59
52wk Low:2.74
Shares:95.60M
Float Shares:79.40M
Volume Ratio:1.52
T/O Rate:2.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2031
EPS(LYR):-3.9514
ROE:-32.54%
ROA:-8.59%
PB:0.98
PE(LYR):-0.79

Loading ...

Myriad Genetics Shares Fall After Piper Sandler Downgrade

MT Newswires Live
·
23 mins ago

U.S. Stocks on the MOVE-GoPro, TXNM Energy, Emergent BioSolutions

Reuters
·
Yesterday

U.S. Stocks on the MOVE-Robinhood Markets, Park Hotels & Resorts, Capricor Therapeutics

Reuters
·
Yesterday

Myriad Genetics downgraded to Underweight from Overweight at Piper Sandler

TIPRANKS
·
Yesterday

Analyst Cuts Myriad Genetics to Sell, Slashes Price Target to $2 Amid Structural Profitability Concerns

TIPRANKS
·
Yesterday

Myriad Genetics Shares Down 4.3% Premarket After Piper Sandler Cuts to Underweight from Overweight

THOMSON REUTERS
·
Yesterday

Myriad Genetics, Inc. : Piper Sandler Cuts to Underweight from Overweight; Cuts Target Price to $2 from $5.45

THOMSON REUTERS
·
Yesterday

Myriad Genetics to Present at Wells Fargo Healthcare Conference

Reuters
·
Aug 27

Myriad Genetics, Inc. : Jefferies Cuts Target Price to $2.5 from $4

THOMSON REUTERS
·
Aug 21

Myriad Genetics is Maintained at Equal-Weight by Stephens & Co.

Dow Jones
·
Aug 18

Myriad Genetics is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
Aug 03

Analysts Have Conflicting Sentiments on These Healthcare Companies: AptarGroup (ATR), Myriad Genetics (MYGN) and HCA Healthcare (HCA)

TIPRANKS
·
Aug 03

Analysts Conflicted on These Healthcare Names: Myriad Genetics (MYGN) and Biodesix (BDSX)

TIPRANKS
·
Aug 01

Myriad Genetics is Maintained at Hold by TD Cowen

Dow Jones
·
Aug 01

Myriad Genetics Down over 45%, on Pace for Record Percent Decrease

Dow Jones
·
Aug 01

Myriad Genetics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 31

Myriad Genetics: Q2 Miss, Guidance Cut Lead to Lower $4 Price Target and Maintained Hold Rating

TIPRANKS
·
Jul 31

Myriad Genetics Lowers FY26 Rev Outlook

Dow Jones
·
Jul 31

Myriad Genetics cuts FY26 revenue view to $770M-$790M from $860M-$880M

TIPRANKS
·
Jul 31

Myriad Genetics reports Q2 EPS (25c), consensus (6c)

TIPRANKS
·
Jul 31